Workshop on benefit-risk of medicines used during pregnancy and breastfeeding
Medicine use in pregnancy is common for treating acute as well as chronic disorders. This includes use while the woman does not yet know she is pregnant, and treatments for conditions that can be pregnancy-specific, worsened by pregnancy, or require continued medication during pregnancy. In Europe, very few medicines are licensed explicitly for use in pregnancy and breastfeeding. This is due to the limited understanding of benefits and risks to mother and child and how they should be balanced.
It is EMA’s ambition that in the medium- to long term, women should have sufficient information, provided appropriately, to enable decision making on their medical treatment, given their (plans for) pregnancy or given they wish to breastfeed their baby.
The PCWP and HCPWP would like to provide an opportunity for their members and the wider stakeholder community to contribute towards developing and implementing EMA’s strategy for developing better information regarding benefits and risks of medicines in pregnancy and breastfeeding, and to encourage a discussion on how to progress towards obtaining evidence on medicine utilisation and safety for this population.
The workshop will be broadcast live. You can follow the broadcast available on the ‘Live broadcast' section on the event page on the day of the event. We will ask for audience participation using an interactive polling platform, through which participants will be asked their views on a range of issues around this topic. A video recording will be available after the event.
Workshop Objectives
- Share experiences and expectations from real life and clinical practice;
- Provide input into the draft EMA strategy on drug safety in pregnancy and breastfeeding;
- Discuss how to progress with implementing the 'EMA strategy towards obtaining evidence on medicine utilisation and safety for pregnant and breastfeeding women' report.
In addition to the online broadcast, there is some - very limited - capacity to participate in the virtual meeting room for people who wish to make verbal contributions to the meeting. Participation in this virtual meeting room is subject to prior application. To submit an expression of interest, complete the registration form.
The deadline for expression of interests is 17 August 2020 5pm CET. Available places will be distributed by different stakeholders on the basis of their EU-wide representation and/or expressed motivation to contribute to the discussion.
You should see the live broadcast on pressing the 'play' icon in the video window, or a message stating that we are not currently broadcasting. To optimise video quality, once the video is playing we recommend clicking on the ‘HD’ symbol in the video window then selecting the '720p' option. If the video window is blank, or if you experience other difficulties viewing the broadcast, please try connecting directly to the Ustream channel. For technical information about the required network security settings, please see this Ustream help page. For further assistance, please consult the EMA service desk. |